Perioperative Durvalumab in Bladder Cancer.

The New England journal of medicine 2025 Feb 06

Related Questions

Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?

New answer by Medical Oncologist at Mayo Clinic Comprehensive Cancer Center (May 13, 2025)

This is another unanswered question through the NIAGARA trial since all patients, including the ones who have pT0 after cystectomy, were treated with adjuvant durvalumab; henc...

Related Questions

Why do I have to sign in?